About Ivabradine
Ivabradine is a heart-rate lowering drug that selectively inhibits the If ("funny") current in the sinoatrial (SA) node. By slowing the diastolic depolarization of SA nodal cells, it reduces heart rate without affecting myocardial contractility, blood pressure, or intracardiac conduction. It is used mainly in stable angina and in chronic heart failure with reduced ejection fraction, but only when the patient is in normal sinus rhythm.
Analysis of the Statements
- Statement 1 (use in severe heart failure) — Correct. Ivabradine is approved as an add-on therapy in symptomatic chronic heart failure with reduced ejection fraction (HFrEF), in patients who are in sinus rhythm with a resting heart rate ≥70 bpm despite optimal beta-blocker therapy (or when beta-blockers are contraindicated/not tolerated).
- Statement 2 (acts on SA node) — Correct. Its mechanism of action is specific inhibition of the If current in the SA node, which is the site of the heart's natural pacemaker activity. This is precisely why it lowers heart rate selectively without other hemodynamic effects.
- Statement 3 (reduces heart rate) — Correct. Slowing SA nodal depolarization directly produces a dose-dependent reduction in heart rate; this bradycardic effect is the basis of its therapeutic use in angina and heart failure.
- Statement 4 (effective in atrial fibrillation) — Incorrect. Ivabradine's action depends entirely on a functioning, rhythmically firing SA node driving the heart. In atrial fibrillation, the SA node is not the pacemaker driving ventricular rate — chaotic atrial activity is conducted irregularly through the AV node — so Ivabradine has no reliable rate-controlling effect and is not indicated for AF. In fact, new-onset or worsening atrial fibrillation is a recognized adverse effect of Ivabradine, making it an inappropriate (and potentially unsafe) choice in this setting.
Conclusion
Statements 1, 2, and 3 correctly describe Ivabradine, while statement 4 is false because the drug requires sinus rhythm to work and is not effective (and is even relatively contraindicated) in atrial fibrillation.
The correct answer is 1, 2 and 3.
